Amgen Inc at Oppenheimer Healthcare Life Sciences Conference Transcript
Hello, everyone, and welcome to Oppenheimer's 34th Annual Healthcare Conference. I'm Jay Olson, one of the biotech analysts at Oppenheimer. Thank you all for joining us here today. It's my pleasure to welcome Amgen to our conference, and it's an honor to introduce Justin Claeys, Head of IR; Susan Sweeney, Head of Global Marketing Access and Capabilities; Murdo Gordon, Head of Global Commercial Operations; and Jay Bradner, Head of R&D.
So we have an amazing lineup here today. And it's great to see all of you and really appreciate you making time for us today. Thank you so much.
Great. Thank you, Jay. We're really glad to be here today. It's an exciting time at Amgen, and we appreciate the chance to share why we're so optimistic about our growth potential.
We see many opportunities across our 4 therapeutic area pillars: General Medicine, Oncology, Inflammation and Rare Disease. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |